This Day On The Street
Continue to site
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Adam's Most Recent Article

Struggling Sanofi Sends Cancer SOS to Regeneron and Another Vanity Biotech IPO Launches

07/28/15 - 10:23 AM EDT

It's a day that ends in "day," which means cancer immunotherapy is dominating the biotech news.

read more >

Other Articles by Adam

Free Reports

Gilead Can Soothe Biotech Investor Fears with Great 2Q Earnings Gilead Can Soothe Biotech Investor Fears with Great 2Q Earnings

07/27/15 - 12:42 PM EDT

Investor confidence in biotech stocks is shaky following last week's Biogen blow-up, making Tuesday's Gilead earnings even more important.

read more >
Biogen's Possible Takeout Targets and Other Key Questions After Blow-Up Biogen's Possible Takeout Targets and Other Key Questions After Blow-Up

07/27/15 - 10:30 AM EDT

After cutting its revenue growth forecast, will Biogen buy itself back into investors' good graces?

read more >
Xoma Is a Biotech Zombie in Need of a Kill Shot to the Head Xoma Is a Biotech Zombie in Need of a Kill Shot to the Head

07/22/15 - 10:41 AM EDT

After 34 years in existence, Xoma still can't develop a drug successfully on its own.

read more >
Eli Lilly's Solanezumab Is the Alzheimer's Drug Equivalent of the Internet Dress Eli Lilly's Solanezumab Is the Alzheimer's Drug Equivalent of the Internet Dress

07/22/15 - 07:00 AM EDT

Lilly uses a new but contentious methodology to suggest treatment benefit from its experimental Alzheimer's drug.

read more >
FDA Closing In on November Expert Panel Date for BioMarin, Sarepta Drugs FDA Closing In on November Expert Panel Date for BioMarin, Sarepta Drugs

07/20/15 - 02:10 PM EDT

Biotech investors, circle November 23 and 24 on your calendars. Use a thick black marker. This will be an epic event for biotech investors.

read more >
Exelixis Scores Much-Needed Kidney Cancer Study Win to Boost Drug Sales Exelixis Scores Much-Needed Kidney Cancer Study Win to Boost Drug Sales

07/20/15 - 07:01 AM EDT

Exelixis plans to seek expanded approval for Cometriq to treat kidney cancer in early 2016.

read more >
Biotech Stock Mailbag: Alzheimer's Conference Preview, Why Stock Prices Sometimes Lie Biotech Stock Mailbag: Alzheimer's Conference Preview, Why Stock Prices Sometimes Lie

07/17/15 - 06:45 AM EDT

Biotech columnist Adam Feuerstein answers readers' questions about health care.

read more >
Thoughts, Appraisals, Lingering Questions From Celgene's $7 Receptos Buy Thoughts, Appraisals, Lingering Questions From Celgene's $7 Receptos Buy

07/15/15 - 09:45 AM EDT

Receptos' ozanimod is one of the most compelling late-stage assets in biotech, which makes Celgene's decision to buy it look smart.

read more >
Gilead Hep C Sales Under Investor Microscope as Earnings Near Gilead Hep C Sales Under Investor Microscope as Earnings Near

07/13/15 - 12:01 PM EDT

The total number of prescriptions written for Gilead Sciences hepatitis C drugs Sovaldi and Harvoni in the U.S. peaked in March and are now in a consistent downtrend.

read more >
Page 1 of 338
< Previous
Top Rated Stocks Top Rated Funds Top Rated ETFs